MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
+0.280
+7.61%
After Hours: 4.050 +0.09 +2.27% 17:53 01/28 EST
OPEN
3.680
PREV CLOSE
3.680
HIGH
4.190
LOW
3.680
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
6.00
52 WEEK LOW
0.7090
MARKET CAP
416.43M
P/E (TTM)
-2.8834
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADAP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADAP News

  • Adaptimmune's Data In Treating Solid Tumors Reinforces Prior Data And Highlights Technology Platform
  • Seeking Alpha - Article.1d ago
  • Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
  • GlobeNewswire.4d ago
  • Adaptimmune +3% premarket after pricing equity offering
  • seekingalpha.6d ago
  • Philadelphia cell therapy company prices $84M public stock offering
  • American City Business Journals.6d ago

More

Industry

Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About ADAP

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
More

Webull offers Adaptimmune Therapeutics PLC - ADR (ADAP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.